Market news

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the […]

IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

Detailed price information for Idexx Laboratories (IDXX-Q) from The Globe and Mail including charting and trades.

IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm, including Taenia and Echinococcus species. "This advancement reflects how we innovate at IDEXX, developing platforms that grow with our customers as care evolves," said...

IDEXX Laboratories (IDXX) said Wednesday it has acquired CoVetAI, a provider of AI-based software th

Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.

Despite trailing the Dow over the past year, IDEXX still has Wall Street on its side, with analysts maintaining a cautiously optimistic view on its future prospects.

249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With ConfidenceDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, by Animal, by Application, by Place, by Product, and by Country 2026 to 2030" report has been added to ResearchAndMarkets.com's offering. The Veterinary Diagnostics industry is on a strong growth path

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).

IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.

IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]

Detailed price information for Idexx Laboratories (IDXX-Q) from The Globe and Mail including charting and trades.

IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre

Detailed price information for Achieve Life Sciences Inc (ACHV-Q) from The Globe and Mail including charting and trades.